Skip to content

Royalty Pharma RPRX Return on assets

Return on assets at other companies

Roivant Sciences logo
Roivant SciencesROIV
-14.7%-15.2pp
ALN
Alnylam PharmaceuticalsALNY
10.8%+8.0pp
Viatris logo
ViatrisVTRS
-0.8%-0.4pp
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
15.6%+7.0pp
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
8.1%+2.5pp
Amgen logo
AmgenAMGN
8.6%+2.1pp

Other financials

Income statement

See full
Revenue$630.6M+11.0%
Operating income$563.0M+5.4%
Net income$294.7M+23.1%
EPS (diluted)$0.67+21.8%

Balance sheet

See full
Cash & equivalents$586.4M-46.1%
Total debt$9.0B+17.8%
Total equity$9.9B+1.6%
Total assets$19.8B+12.5%

Cash flow

See full
Operating cash flow$718.2M+20.5%

Valuation

See full
Market cap$23.48B+52.4%
Enterprise value$31.86B+44.6%
P/E28.4×+14.3×
P/S9.6×+2.8×

Profitability

See full
Operating margin65.1%-18.9pp
Net margin33.9%-14.4pp

Returns & leverage

See full
Return on equity8.4%-2.7pp
Debt / equity0.9×+0.1×
Current ratio2.7×+1.1×

Where this comes from

Calculated from Royalty Pharma’s reported figures.

Based on trailing twelve months.

The official record: Royalty Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Royalty Pharma's return on assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Royalty Pharma's return on assets?
Royalty Pharma (RPRX) reported return on assets of 4.4% in Q1 2026.
How has Royalty Pharma's return on assets changed year-over-year?
Royalty Pharma's return on assets decreased by 31.8% year-over-year, from 6.5% to 4.4%.
What does return on assets mean?
How much profit the company squeezes out of everything it owns.
How do you interpret return on assets?
Higher means more productive assets. Unlike ROE, it is unaffected by leverage, so a wide ROE-minus-ROA gap flags a heavily levered balance sheet.
How does return on assets compare across companies?
Best compared within an industry — asset intensity varies enormously across sectors. Not meaningful for banks, whose assets are largely financial.